| Patent Number |
Title Of Patent |
Date Issued |
| 6984729 |
Oligonucleotides specific for hepatitis B virus |
January 10, 2006 |
| The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions. |
| 6946447 |
MDM2-specific antisense oligonucleotides |
September 20, 2005 |
| The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of tra |
| 6936593 |
Method of down-regulating gene expression |
August 30, 2005 |
| Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate |
| 6815429 |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucl |
November 9, 2004 |
| The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for i |
| 6667293 |
Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
December 23, 2003 |
| The present invention provides a method of reducing the immunostimulatory effects of certain phosphorothioate oligonucleotides used to treat pathogen-mediated disease states and other medical conditions. Immunostimulatory effects of phosphorothioate oligonucleotides are reduced in ac |
| 6649596 |
Modified VEGF Oligonucleotides for Inhibition of tumor growth |
November 18, 2003 |
| Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogene |
| 6645943 |
Method of down-regulating gene expression |
November 11, 2003 |
| Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate |
| 6624293 |
Modified protein kinase A-specific oligonucleotides and methods of their use |
September 23, 2003 |
| Disclosed are synthetic, modified oligonucleotides complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI.sub..alpha.. The modified oligonucleotides have from about 15 to about 30 nucleotides and are hybrid, inverted hybr |
| 6608035 |
Method of down-regulating gene expression |
August 19, 2003 |
| Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate |
| 6605708 |
Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
August 12, 2003 |
| The invention provides synthons containing a novel carbamate internucleoside linkage, methods for using such synthons to make oligonucleotides containing such novel carbamate linkages, and oligonucleotides containing such novel carbamate linkages. |
| 6531589 |
Base protecting groups and synthons for oligonucleotide synthesis |
March 11, 2003 |
| The invention provides new methods for synthesizing oligonucleotides that allow for deprotection of the oligonucleotides under more mild conditions than existing methods. The invention further provides a nucleoside base protecting group that is stable under oligonucleotide synthesis |
| 6509459 |
Base protecting groups and rapid process for oligonucleotide synthesis |
January 21, 2003 |
| The invention provides new processes for synthesizing oligonucleotides that allow for deprotection of the oligonucleotide under more rapid and/or more mild conditions than existing methods.The invention further provides a nucleoside base protecting group that is stable under oligonucleot |
| 6509149 |
HPV-specific oligonucleotides |
January 21, 2003 |
| The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhi |
| 6489464 |
Branched oligonucleotides as pathogen-inhibitory agents |
December 3, 2002 |
| Novel antisense oligonucleotides are disclosed. The present oligonucleotides have increased resistance to nuclease attack and manifest increased efficacy in combating pathogenic infections. The present oligonucleotides comprise two or more identical or different sequences, each compl |
| 6489304 |
Hyperstructure-forming carriers |
December 3, 2002 |
| Disclosed are bioactive substances useful for the delivery of effector units in animals. Also disclosed are methods for utilizing the bioactive substances of the invention. |
| 6485973 |
Oligonucleotides specific for the marORAB operon |
November 26, 2002 |
| Disclosed are synthetic oligonucleotides complementary to a transcript of the marORAB operon which inhibit expression of a gene in the operon. Also disclosed are methods of reducing bacterial resistance to antibiotics, and pharmaceutical formulations containing marORAB-specific oligonucl |
| 6476000 |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucl |
November 5, 2002 |
| The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for |
| 6458940 |
HPV-specific oligonucleotides |
October 1, 2002 |
| The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhi |
| 6440660 |
Oligonucleotide mediated reversal of drug resistance |
August 27, 2002 |
| The present invention provides methods of resensitizing an anti-drug-resistant infectious agent to a drug. Also disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to a region of pfmdr1 nucleic acid, and methods of down-regulating the expression of pfm |
| 6426334 |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
July 30, 2002 |
| The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1.beta. and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon |
| 6399586 |
Modified VEGF oligonucleotides |
June 4, 2002 |
| Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogene |
| 6383752 |
Pseudo-cyclic oligonucleobases |
May 7, 2002 |
| The present invention comprises a new class of oligonucleobases (e.g., oligonucleotides), which we call "pseudo-cyclic oligonucleotides" (PCOs). PCOs contain two oligonucleotide segments attached through their 3'-3' or 5'-5' ends. One of the segments (the "functional segment") of the PCO |
| 6372427 |
Cooperative oligonucleotides |
April 16, 2002 |
| Disclosed is a composition comprising at least two synthetic, cooperative oligonucleotides, each comprising a region complementary to one of tandem, non-overlapping regions of a target single-stranded nucleic acid, and each further comprising a dimerization domain at a terminus of each o |
| 6346614 |
Hybrid oligonucleotide phosphorothioates |
February 12, 2002 |
| The invention provides hybrid oligonucleotides having phosphorothioate or phosphorodithioate internucleotide linkages, and both deoxyribonucleosides and ribonucleosides or 2'-substituted ribonucleosides. Such hybrid oligonucleotides have superior properties of duplex formation with RNA, |
| 6335436 |
Oligonucleotides active against drug-resistant bacteria |
January 1, 2002 |
| The invention discloses methods and materials for the utilization of chemically modified oligonucleotides in the treatment of drug-resistant bacterial infections including drug-resistant tuberculosis. |
| 6306829 |
Modified VEGF oligonucleotides for treatment of skin disorders |
October 23, 2001 |
| Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogene |
| 6140482 |
Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same |
October 31, 2000 |
| The invention provides new primary phosphoramidate internucleoside linkages that are less sterically constrained than existing phosphoramidate linkages, as well as oligonucleotides containing such linkages and processes for making and methods for using such oligonucleotides. |
| 6117993 |
Synthons for oligonucleotide synthesis |
September 12, 2000 |
| The invention provides new reagents and processes for synthesizing oligonucleotides, including stereoselective oligonucleotide synthesis. In a first aspect, the invention provides novel monomer synthons for the synthesis of oligonucleotides. Monomer synthons according to this aspect |
| 6117992 |
Reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleo |
September 12, 2000 |
| The invention provides new methods for synthesizing oligonucleotides containing at least one, and preferably all phosphorodithioate internucleoside linkages with less than 5% phosphoromonothioate contamination. This level of purity in the synthesis of phosphorodithoates has previousl |
| 6096881 |
Sulfur transfer reagents for oligonucleotide synthesis |
August 1, 2000 |
| In our research, two commercially available compounds, 3-amino-1,2,4-dithiazole-5-thione (1) and xanthane hydride (2), and their derivatives 3-6 are found to be potential sulfur-transfer reagents. The efficiency and optimization of these new sulfur-transfer reagents were investigated |
| 6087491 |
Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
July 11, 2000 |
| The present invention comprises an improved method of synthesizing oligonucleotides. The method comprises employing dinucleotides (or "dimer blocks") as the basic synthetic unit building block. The method results in extremely high purity oligonucleotides in which the N-1 content is very |
| 6054439 |
Antisense olignucleotides having tumorigenicity-inhibiting activity |
April 25, 2000 |
| The invention encompasses tumorigenicity-inhibiting antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprising t |
| 6013786 |
MDM2-specific antisense oligonucleotides |
January 11, 2000 |
| The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of tra |
| 5973136 |
Inverted chimeric oligonucleotides |
October 26, 1999 |
| The invention relates to modified oligonucleotides that are useful for studies of gene expression and for the antisense therapeutic approach. The invention provides inverted hybrid oligonucleotides and inverted chimeric oligonucleotides, both of which produce reduced side effects, relati |
| 5969117 |
Modified protein kinase a-specific oligonucleotide |
October 19, 1999 |
| Disclosed are synthetic, modified oligonucleotides complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI.sub.60. The modified oligonucleotides have from about 15 to about 30 nucleotides and are hybrid, inverted hybrid, or |
| 5968909 |
Method of modulating gene expression with reduced immunostimulatory response |
October 19, 1999 |
| The present invention provides a method of reducing the immunostimulatory effects of certain phosphorothioate oligonucleotides used to treat pathogen-mediated disease states and other medical conditions. Immunostimulatory effects of phosphorothioate oligonucleotides are reduced in ac |
| 5962674 |
Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
October 5, 1999 |
| The invention provides new reagents and an improved process for synthesizing oligonucleotides that contain methylphosphonate internucleoside linkages. The reagents and process utilize a nucleoside base protecting group that is stable under oligonucleotide synthesis conditions, but wh |
| 5955599 |
Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside l |
September 21, 1999 |
| The invention provides oligonucleotides containing methyl phosphotriester linkages and processes for making and methods for using such oligonucleotides. |
| 5929226 |
Antisense oligonucleotide alkylphosphonothioates and arylphospohonothioates |
July 27, 1999 |
| The invention provides improved oligonucleotides having greater resistance to nucleolytic degradation by virtue of having alkylphosphonothioate or arylphosphonothioate internucleotide linkages. |
| 5919772 |
Antisense oligonucleotides having tumorigenicity-inhibiting activity |
July 6, 1999 |
| The invention encompasses tumorigenicity-inhibitiig antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprising t |
| 5912332 |
Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
June 15, 1999 |
| The present invention provides novel compounds and methods for purifying oligonucleotides. The compounds according to the invention are multimeric oligonucleotides comprising a multimerization domain for inducing multimeric oligonucleotide aggregation, a hybridization domain that is |
| 5886165 |
Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonu |
March 23, 1999 |
| The present invention provides a novel class of oligonucleotides useful for antisense purposes. The oligonucleotides of the invention comprise both deoxyribonucleotides with "natural" 3'-5' internucleotide linkages and ribonucleotides with 2'-5' internucleotide linkages. Because of their |
| 5877308 |
CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer |
March 2, 1999 |
| Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to CAPL nucleic acid. Also disclosed are methods of inhibiting the expression of CAPL gene and methods of inhibiting metastatic cancer using CAPL-specific oligonucleotides. |
| 5872007 |
CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer |
February 16, 1999 |
| Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to CAPL nucleic acid. Also disclosed are methods of inhibiting the expression of CAPL gene and methods of inhibiting metastatic cancer using CAPL-specific oligonucleotides. |
| 5866699 |
Oligonucleotides with anti-MDR-1 gene activity |
February 2, 1999 |
| Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligon |
| 5856459 |
Oligonucleotides specific for hepatitis B virus |
January 5, 1999 |
| The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions. |
| 5847104 |
Method of tritium labeling oligonucleotide |
December 8, 1998 |
| The present invention comprises a novel method of incorporating a tritium label at one or more predetermined sites within an oligonucleotide. In particular, the method comprises contacting a nascent, support-bound oligonucleotide having a free 5' hydroxyl group with a suitable oxidizing |
| 5833944 |
Procedure for the solid phase synthesis of .sup.35 S-labeled oligonucleotides with 3H-1,2-benzod |
November 10, 1998 |
| This invention provides a novel compound for .sup.35 S-labelling oligonucleotides. The compound is .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1) ##STR1## wherein the asterisk indicates the position of the .sup.35 S. Also provided is a method of synthesizing this compound, c |
| 5814620 |
Inhibition of neovascularization using vegf-specific oligonucleotides |
September 29, 1998 |
| Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in |
| 5808042 |
Detritylation of DMT-oligonucleotides using cationic ion-exchange resin |
September 15, 1998 |
| The present invention comprises a method for quickly and efficiently detritylating oligonucleotides synthesized by standard chemical techniques. The method comprises contacting a 5'-DMT oligonucleotide with the H.sup.+ form of a "DOWEX," "AMBERLYST" or "AMBERLITE" ion-exchange resin |
